These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33629064)

  • 21. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
    Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
    J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An animal model of MYC-driven medulloblastoma.
    Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
    Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma.
    Fiaschetti G; Castelletti D; Zoller S; Schramm A; Schroeder C; Nagaishi M; Stearns D; Mittelbronn M; Eggert A; Westermann F; Ohgaki H; Shalaby T; Pruschy M; Arcaro A; Grotzer MA
    Oncogene; 2011 Jun; 30(25):2823-35. PubMed ID: 21317922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective Inhibition of
    Zhao Y; Li T; Tian S; Meng W; Sui Y; Yang J; Wang B; Liang Z; Zhao H; Han Y; Tang Y; Zhang L; Ma J
    Cancer Manag Res; 2020; 12():12473-12485. PubMed ID: 33299354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma.
    Wang D; Pierce A; Veo B; Fosmire S; Danis E; Donson A; Venkataraman S; Vibhakar R
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33494392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
    Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
    Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition.
    Graziani V; Garcia AR; Alcolado LS; Le Guennec A; Henriksson MA; Conte MR
    Sci Rep; 2023 Jan; 13(1):1273. PubMed ID: 36690651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma.
    Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y
    J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma.
    Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S
    Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification.
    Ćwiek P; Leni Z; Salm F; Dimitrova V; Styp-Rekowska B; Chiriano G; Carroll M; Höland K; Djonov V; Scapozza L; Guiry P; Arcaro A
    Oncotarget; 2015 Jan; 6(1):116-29. PubMed ID: 25402633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.
    Spender LC; Inman GJ
    Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
    Pei Y; Liu KW; Wang J; Garancher A; Tao R; Esparza LA; Maier DL; Udaka YT; Murad N; Morrissy S; Seker-Cin H; Brabetz S; Qi L; Kogiso M; Schubert S; Olson JM; Cho YJ; Li XN; Crawford JR; Levy ML; Kool M; Pfister SM; Taylor MD; Wechsler-Reya RJ
    Cancer Cell; 2016 Mar; 29(3):311-323. PubMed ID: 26977882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
    Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
    J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
    Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
    Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
    Qin N; Paisana E; Langini M; Picard D; Malzkorn B; Custódia C; Cascão R; Meyer FD; Blümel L; Göbbels S; Taban K; Bartl J; Bechmann N; Conrad C; Gravemeyer J; Becker JC; Stefanski A; Puget S; Barata JT; Stühler K; Fischer U; Felsberg J; Ayrault O; Reifenberger G; Borkhardt A; Eisenhofer G; Faria CC; Remke M
    Neuro Oncol; 2022 Sep; 24(9):1509-1523. PubMed ID: 35307743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mouse medulloblastoma driven by CRISPR activation of cellular Myc.
    Vo BT; Kwon JA; Li C; Finkelstein D; Xu B; Orr BA; Sherr CJ; Roussel MF
    Sci Rep; 2018 Jun; 8(1):8733. PubMed ID: 29880921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.
    Reiher FK; Volpert OV; Jimenez B; Crawford SE; Dinney CP; Henkin J; Haviv F; Bouck NP; Campbell SC
    Int J Cancer; 2002 Apr; 98(5):682-9. PubMed ID: 11920636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma.
    Kameda-Smith MM; Zhu H; Luo EC; Suk Y; Xella A; Yee B; Chokshi C; Xing S; Tan F; Fox RG; Adile AA; Bakhshinyan D; Brown K; Gwynne WD; Subapanditha M; Miletic P; Picard D; Burns I; Moffat J; Paruch K; Fleming A; Hope K; Provias JP; Remke M; Lu Y; Reya T; Venugopal C; Reimand J; Wechsler-Reya RJ; Yeo GW; Singh SK
    Nat Commun; 2022 Dec; 13(1):7506. PubMed ID: 36473869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.
    Xu Z; Murad N; Malawsky D; Tao R; Rivero-Hinojosa S; Holdhof D; Schüller U; Zhang P; Lazarski C; Rood BR; Packer R; Gershon T; Pei Y
    Clin Cancer Res; 2022 Oct; 28(19):4278-4291. PubMed ID: 35736214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis.
    Purvis IJ; Avilala J; Guda MR; Venkataraman S; Vibhakar R; Tsung AJ; Velpula KK; Asuthkar S
    J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31382461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.